Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



Live Q&A: Overcoming Barriers to the Use of Long-Acting Injectables in Schizophrenia Management: Because Every Patient Deserves Recovery

Premiere Date: Thursday, January 13, 2022

This activity offers CE credit for:

  1. Medicine (accme)
  2. Nursing (ANCC)
  3. Pharmacy (acpe)
  4. PA (aapa)
  5. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Friday, January 13, 2023

Faculty


Christoph U. Correll, MDChristoph U. Correll, MD 
Professor of Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY
Professor and Chair of the Department of Child and Adolescent Psychiatry
Charité University Medicine
Berlin, Germany
Investigator, Center for Psychiatric Neuroscience
Feinstein Institute for Medical Research
Manhasset, NY
Medical Director, Recognition and Prevention (RAP) Program
The Zucker Hillside Hospital, Department of Psychiatry
Glen Oaks, NY

Statement of Need

As a chronic, debilitating disorder, schizophrenia necessitates early detection and optimal management, particularly within the context of impeding factors such as medical comorbidities, lack of confidence in the use of long-acting injectables (LAIs), and racial disparities.

In this Q&A session, Dr. Correll will address queries on tools to develop effective, evidence-based treatment strategies for schizophrenia within the context of patient preferences and goals. These strategies include insight and ideal practices to address racial disparities and optimal selection and use of LAIs to enable patients to maintain and sustain a successful treatment plan, promoting remission and recovery of function.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Employ best practices for the management of patients with schizophrenia at high risk for adverse events.
  • Formulate practice strategies for the use of LAIs in patients with schizophrenia while considering treatment initiation, dose, and dosing schedules.
  • Implement strategies to address racial disparities in the diagnosis and management of schizophrenia by removing implicit bias, establishing trust, providing education, and engaging in shared decision-making.

Financial Support

Supported by an educational grant from Alkermes.

Target Audience

Psychiatrists, psychiatric residents, psychiatric nurses, primary care physicians, PAs, nurse practitioners, and pharmacists

Credit Information



Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Correll reports that he receives grants and research support from Janssen Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for AbbVie Inc.; Acadia Pharmaceuticals Inc.; Alkermes; Allergan; Angelini Pharma Inc.; Aristo Pharma; Axsome Therapeutics, Inc.; Damitsa; Gedeon Richter; Hikma Pharmaceuticals; IntraCellular Therapies; Janssen Pharmaceuticals, Inc./ Johnson & Johnson; LB Pharmaceuticals.; Lundbeck; Medavante-ProPhase, Inc; MedinCell; Merck & Co., Mitsubishi Tanabe Pharma Corporation; Mylan Pharmaceuticals, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Recordati; Rovi; Servier; Sumitomo Dainippon Pharma Co., Ltd.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A. Inc.; Teva Pharmaceutical Industries Ltd.; and Viatris Inc. He receives royalties from UpToDate.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

SNQ-140-011322-64

Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download